Key facts
- It has raised $260.5M; the latest was Early Stage VC ($110.0M) in Nov 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, Shenzhen Capital Group, Qiming Venture Partners, GL Ventures, Legend Capital — 25 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for SanegeneBio
- ·The full record, as it builds
Funding rounds
No funding rounds for SanegeneBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SanegeneBio
Developer of RNA interference (RNAi) therapeutics intended to knock down disease-causing genes. The company offers products that are constructed and developed with RNA technology and are able to achieve specific delivery of multiple RNA drugs, thereby effectively knocking out disease-causing genes, providing treatment for patients with cardiometabolic diseases, infectious diseases, central nervous system and eye diseases.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Website
- sanegenebio.com/
- Ownership
- Privately Held (backing)
SanegeneBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SanegeneBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SanegeneBio in its N-PORT filings yet. We sweep new filings monthly.